Venus Remedies vs Peers
- Market cap
- ₹2,165 crore
- P/E
- 22.5
- P/B
- 2.85
- ROE
- 14.5%
- Dividend yield
- 1.20%
- 52-week range
- ₹1,166.11 – ₹2,186.46
Venus Remedies ranks 1st by market capitalisation among 1 Drug Manufacturers - Specialty & Generic companies tracked by ATS. Its largest peers are Venus Remedies. Its P/E of 22.5 compares with a peer median of 22.5.
Venus Remedies vs Drug Manufacturers - Specialty & Generic peers
Sorted by market capitalisation.
| Company | Close (₹) | 1D | Market cap (₹ cr) | P/E | P/B | ROE | 1Y return |
|---|---|---|---|---|---|---|---|
| Venus Remedies | 1,619.60 | -8.47% | 2,165 | 22.5 | 2.85 | 14.5% | +18.5% |
| Venus Remedies | 1,619.60 | -8.47% | 2,165 | 22.5 | 2.85 | 14.5% | +24.5% |
Source: NSE end-of-day prices; ratios from company filings. Data as of 9 October 2026. How this data is compiled.
Venus Remedies peer comparison — frequently asked questions
Who are Venus Remedies' competitors?
Venus Remedies' listed peers in Drug Manufacturers - Specialty & Generic include Venus Remedies, ranked here by market capitalisation.
How does Venus Remedies' P/E compare with its peers?
Venus Remedies trades at a P/E of 22.5, against a median of 22.5 across the 1 Drug Manufacturers - Specialty & Generic peers shown.
Which is the largest company among Venus Remedies' peers?
By market capitalisation, the largest company in the group is Venus Remedies at ₹2,165 crore, against ₹2,165 crore for Venus Remedies.
Same Data For Peers
Trade Venus Remedies With ATS
Track VENUSREM live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.
Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.